

Association of inflammatory markers with the clinical phenotype and prognosis of Guillain-Barré Syndrome

Aymen Ellouze (1), Sabrina Mejdoub (1), Nouha Farhat (2), Sawsan Feki (1), Mariem Dammak (2), Hend Hachicha (1)

(1) Immunology Laboratory, Habib Bourguiba University Hospital, Sfax, Tunisia

(2) Neurology Department, Habib Bourguiba University Hospital, Sfax, Tunisia

Introduction



Patients and Methods

- Prospective study since January 2022
- Inclusion of patients from the Neurology department with a GBS diagnosis
- Collection of the results of inflammatory markers at admission: CRP and complete blood count (CBC)

Calculation of blood cell ratios: NLR, MLR, MNR, PNR, and PLR

Collection of blood samples at admission

Assessment of serum levels of C3 and C4 complement fractions using turbidimetry (Optilite®)

Normal values: C3: 0.65-1.45 g/L ; C4: 0.1-0.4 g/L

Evaluation of clinical severity : monthly, using the GBS Disability Score (GDS), during a six-months-follow-up period



4) Jahan I. Neutrophil-lymphocyte ratio in Guillain-Barré syndrome: A prognostic biomarker of severe disease and mechanical ventilation in Bangladesh. J Peripher Nerv Syst. 2023 Mar;28(1):47-57. doi: 10.1111/jns.12531. Epub 2023 Feb 8. PMID: 36700342;